GSK GlaxoSmithKline PLC Common Stoc

42.96
-0.34  -1%
Previous Close 43.30
Open 43.11
Price To book 48.00
Market Cap 104.95B
Shares 2,443,000,000
Volume 3,320,218
Short Ratio 2.04
Av. Daily Volume 2,914,450

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial initiation noted March 31, 2017.
Mepolizumab
Severe hypereosinophilic syndrome (HES)
Phase 3 trial commenced 4Q 2016.
Daprodustat - ASCEND-ND
Anemia
Phase 3 trial commenced August 2016.
Dolutegravir + lamivudine (GEMINI 2)
HIV
Phase 2b data due 2H 2017.
GSK 165
Rheumatoid arthritis
sBLA filing announced March 15, 2017.
Fluarix Quadrivalent (Influenza Vaccine)
Influenza A - children 6-35 months of age.
Phase 3 data due 2017.
Nucala
Chronic obstructive pulmonary disease (COPD)
Phase 3 trial met primary endpoint - December 2016. Filing to be submitted 2017.
Dolutegravir + rilpivirine:
HIV
Phase 3 METREX trial met primary endpoint. Phase 3 METREO failed to meet endpoint.
Mepolizumab
Chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype
Phase 3 trial commenced August 2016.
Dolutegravir + lamivudine (GEMINI 1)
HIV
Phase 3 study completion due 2018.
Closed Triple - CAPTAIN
Asthma
Phase 3 trial commenced 4Q 2016.
Daprodustat - ASCEND-D
Anemia
Phase 3 commenced December 2016.
Cabotegravir long-acting
HIV
Phase 2b trial to be initiated 2017.
Inhaled PI3Kδ inhibitor
Chronic obstructive pulmonary disease (COPD)
Phase 2b data due 2H 2017.
GSK 166
Rheumatoid arthritis
Phase 2 data due 2H 2017.
GSK 165
Osteoarthritis
Phase 2b trial to be initiated May 2017.
Danirixin
Chronic obstructive pulmonary disease (COPD)
BLA filing announced September 23, 2016. PDUFA estimate September 23, 2017.
Sirukumab
Rheumatoid arthritis
BLA filing announced October 24, 2016. PDUFA estimate October 24, 2017.
Shingrix
Shingles
Filing announced Novermber 21, 2016. PDUFA estimate September 21, 2017.
FF/UMEC/VI
Chronic obstructive pulmonary disease (COPD)
BLA filing announced September 23, 2016. PDUFA estimate July 23, 2017.
Benlysta (belimumab) - subcutaneous
Systemic lupus erythematosus (SLE)

Latest News

  1. A Close Look at Merck & Co.’s Valuation after 1Q17 Earnings
  2. Better Buy: Celldex Therapeutics, Inc. vs. Agenus Inc.
  3. Ionis (IONS) Stock Falls Despite Positive Inotersen Data
  4. Citi Prefers These 4 Stocks Over Pfizer On Bottom-Line Concerns
  5. Today's Research Reports on Stocks to Watch: GlaxoSmithKline and Novartis
  6. GlaxoSmithKline Could Buy Out Partner Novartis
  7. Top-10 Glaxo investor Woodford sells out, criticises board
  8. Glaxit: GlaxoSmithKline Sees a Top Investor Dump Stock out of 'Frustration'
  9. Woodford Turns Bullish on Lloyds as He Cuts Ties With Glaxo
  10. [$$] SuperGroup's wholesale change translates into sales
  11. Hikma Shares Plunge After It Says 'Low Likelihood' of 2017 Generic Advair Approval
  12. GlaxoSmithKline Plc : GSK-US: Dividend Analysis : May 12th, 2017 (record date) : By the numbers : May 10, 2017
  13. Better Buy: GlaxoSmithKline vs. Johnson & Johnson
  14. Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q1
  15. Which Big Pharma Is the Best Dividend Stock?
  16. Agenus (AGEN) Reports Narrower-than-Expected Loss in Q1
  17. GSK 'real world' drug test has second success in asthma
  18. Relvar Ellipta Significantly Improved Asthma Control in Salford Lung Study Patients Compared with Their Usual Care
  19. Here's What Wiped $3 Billion Off GlaxoSmithKline's Market Cap in April
  20. What’s GlaxoSmithKline’s Valuation after 1Q17 Earnings?